Psoriatic Arthritis Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | ACELYRIN, Sun Pharma, UCB Pharma, Ventyx Biosciences, Bristol-Myers Squibb, Aclaris Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Psoriatic Arthritis pipeline constitutes 20+ key companies continuously working towards developing 25+ Psoriatic Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Psoriatic Arthritis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriatic Arthritis Market.

The Psoriatic Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Psoriatic Arthritis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Psoriatic Arthritis treatment therapies with a considerable amount of success over the years.

*
Psoriatic Arthritis companies working in the treatment market are ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Biosciences, Inc, Bristol-Myers Squibb, Aclaris Therapeutics, Inc., AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, Affibody AB, Amgen, Eli Lilly and Company, PRA Health Sciences, and others, are developing therapies for the Psoriatic Arthritis treatment

*
Emerging Psoriatic Arthritis therapies in the different phases of clinical trials are- Izokibep, SUNPG18_07, Bimekizumab, VTX958, Deucravacitinib, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others are expected to have a significant impact on the Psoriatic Arthritis market in the coming years.

*
In November 2023, Takeda has reported achieving the primary endpoint in a Phase IIb trial of TAK-279 for patients with active psoriatic arthritis. This randomized, multicenter, double-blind, placebo-controlled, multiple-dose study (NCT05153148) assessed the efficacy, safety, and tolerability of TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next-generation selectivity, in patients with active psoriatic arthritis.

*
In November 2023, Amgen (NASDAQ:AMGN) announced results from the global Phase 4 FOREMOST study evaluating Otezla Registered (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study specifically designed to assess individuals with oligoarticular psoriatic arthritis of five years' duration or less.

Psoriatic Arthritis Overview

Psoriatic arthritis is a form of inflammatory arthritis that affects some people who have psoriasis, a condition characterized by red, scaly skin patches. It can cause joint pain, stiffness, and swelling, and it often affects the fingers and toes.

Get a Free Sample PDF Report to know more about Psoriatic Arthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight [https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Psoriatic Arthritis Drugs Under Different Phases of Clinical Development Include:

*
Izokibep: ACELYRIN Inc.

*
SUNPG18_07: Sun Pharmaceutical Industries Limited

*
Bimekizumab: UCB Pharma

*
VTX958: Ventyx Biosciences, Inc

*
Deucravacitinib: Bristol-Myers Squibb

*
ATI-450: Aclaris Therapeutics, Inc.

*
Risankizumab: AbbVie

*
Upadacitinib: AbbVie

*
AIN457: Novartis

*
Ustekinumab: Janssen Research & Development, LLC

*
Sonelokimab: MoonLake Immunotherapeutics AG

Psoriatic Arthritis Route of Administration

Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Psoriatic Arthritis Molecule Type

Psoriatic Arthritis Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Psoriatic Arthritis Pipeline Therapeutics Assessment

*
Psoriatic Arthritis Assessment by Product Type

*
Psoriatic Arthritis By Stage and Product Type

*
Psoriatic Arthritis Assessment by Route of Administration

*
Psoriatic Arthritis By Stage and Route of Administration

*
Psoriatic Arthritis Assessment by Molecule Type

*
Psoriatic Arthritis by Stage and Molecule Type

DelveInsight's Psoriatic Arthritis Report covers around 25+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Psoriatic Arthritis product details are provided in the report. Download the Psoriatic Arthritis pipeline report to learn more about the emerging Psoriatic Arthritis therapies [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Psoriatic Arthritis Therapeutics Market include:

Key companies developing therapies for Psoriatic Arthritis are - Pfizer Inc., Eisai Inc, UCB Biosciences Inc, Sanofi S.A., Otsuka Pharmaceutical, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Celgene Corporation (Bristol-Myers Squibb), AbbVie Inc., and others.

Psoriatic Arthritis Pipeline Analysis:

The Psoriatic Arthritis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Psoriatic Arthritis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis Treatment.

*
Psoriatic Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Psoriatic Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriatic Arthritis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Psoriatic Arthritis drugs and therapies [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of Psoriatic Arthritis Pipeline Drug Insight

*
Coverage: Global

*
Key Psoriatic Arthritis Companies: ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Biosciences, Inc, Bristol-Myers Squibb, Aclaris Therapeutics, Inc., AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, Affibody AB, Amgen, Eli Lilly and Company, PRA Health Sciences, and others

*
Key Psoriatic Arthritis Therapies: Izokibep, SUNPG18_07, Bimekizumab, VTX958, Deucravacitinib, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others

*
Psoriatic Arthritis Therapeutic Assessment: Psoriatic Arthritis current marketed and Psoriatic Arthritis emerging therapies

*
Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis market drivers and Psoriatic Arthritis market barriers

Request for Sample PDF Report for Psoriatic Arthritis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Psoriatic Arthritis Report Introduction

2. Psoriatic Arthritis Executive Summary

3. Psoriatic Arthritis Overview

4. Psoriatic Arthritis- Analytical Perspective In-depth Commercial Assessment

5. Psoriatic Arthritis Pipeline Therapeutics

6. Psoriatic Arthritis Late Stage Products (Phase II/III)

7. Psoriatic Arthritis Mid Stage Products (Phase II)

8. Psoriatic Arthritis Early Stage Products (Phase I)

9. Psoriatic Arthritis Preclinical Stage Products

10. Psoriatic Arthritis Therapeutics Assessment

11. Psoriatic Arthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Psoriatic Arthritis Key Companies

14. Psoriatic Arthritis Key Products

15. Psoriatic Arthritis Unmet Needs

16 . Psoriatic Arthritis Market Drivers and Barriers

17. Psoriatic Arthritis Future Perspectives and Conclusion

18. Psoriatic Arthritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriatic-arthritis-pipeline-analysis-2024-fda-approvals-and-emerging-therapies-by-delveinsight-acelyrin-sun-pharma-ucb-pharma-ventyx-biosciences-bristolmyers-squibb-aclaris-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.